Trial Profile
DAHANCA 19: a randomized study of the importance of the EGFr inhibitor zalutumumab for the outcome after primary curative radiotherapy for squamous cell carcinoma of the head and neck
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Zalutumumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- 02 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jun 2011 Planned end date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 20 Dec 2007 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.